I agree. Nearly every drug has a proper time, dose
Post# of 148163
Leronlimab may be singularly unique, perhaps in the history of medicine. (Sorry for the hyperbole. Physicians and historians feel free to set me straight).
Lenzilumab I believe will still have a place. I owned shares as it appears effective for mitigating negative effects of CAR-T therapy. I sold my stake in humanigen and Fate therapeutics (CAR-T therapies) to buy more Cytodyn.
I am unable to find a way that leronlimab is not at most of what we believe it to be.
I expect, as expharmer just noted, that tomorrow should be our day.
28 hours, 12 minutes to go.